Cases

Search for a case

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Cases

December 12, 2022

PSB Holding Corp. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of PSB Holding Corp. (“PSB Holding” or the “Company”) (OTC: PSBP) in connection with the proposed merger of the Company with Summit Financial Group, Inc. (“Summit”) (NASDAQ: SMMF). Under the merger agreement, the Company’s shareholders will receive 1.2347 shares of Summit’s common stock for each PSB Holding share, representing implied per-share consideration of $33.51 based upon Summit’s ’s December 9, 2022 closing price of $27.14.

Join Case →

December 12, 2022

Weber Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Weber Inc. (“Weber” or the “Company”) (NYSE: WEBR) in connection with the proposed acquisition of the Company by BDT Capital Partners LLC. Under the terms of the merger agreement, the Company’s shareholders will receive $8.05 in cash for each share of Weber common stock owned.

Join Case →

December 12, 2022

Coupa Software Incorporated Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Coupa Software Incorporated (“Coupa” or the “Company”) (NASDAQ: COUP) in connection with the proposed acquisition of the Company by Thoma Bravo that includes a significant minority investment from a wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”). Under the terms of the merger agreement, the Company’s shareholders will receive $81.00 in cash for each share of Coupa common stock owned.

Join Case →

December 12, 2022

Horizon Therapeutics Public Limited Company Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Horizon Therapeutics Public Limited Company (“Horizon Therapeutics” or the “Company”) (NASDAQ: HZNP) in connection with the proposed acquisition of the Company by Amgen Inc. (NASDAQ: AMGN). Under the terms of the merger agreement, the Company’s shareholders will receive $116.50 in cash for each share of Horizon Therapeutics common stock owned.

Join Case →

December 7, 2022

Vivint Smart Home, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Vivint Smart Home, Inc. (“Vivint” or the “Company”) (NYSE: VVNT), in connection with the proposed acquisition of the Company by NRG Energy, Inc. (NYSE: NRG). Under the terms of the merger agreement, the Company’s shareholders will receive $12.00 in cash for each share of Vivint common stock owned.

Join Case →

December 5, 2022

Salisbury Bancorp, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Salisbury Bancorp, Inc. (“Salisbury” or the “Company”) (NASDAQ: SAL), in connection with the proposed merger of the Company with NBT Bancorp Inc. (“NBT”) (NASDAQ: NBTB). Under the merger agreement, the Company’s shareholders will receive 0.7450 shares of NBT common stock for each Salisbury share, representing implied per-share consideration of $34.47 based upon NBT’s December 2, 2022 closing price of $46.27.

Join Case →

November 29, 2022

Apollo Endosurgery, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Apollo Endosurgery, Inc. (“Apollo Endosurgery” or the “Company”) (NASDAQ: APEN), in connection with the proposed acquisition of the Company by Boston Scientific Corporation (NYSE: BSX). Under the terms of the merger agreement, the Company’s shareholders will receive $10.00 in cash for each share of Apollo Endosurgery common stock owned.

Join Case →

November 23, 2022

Equillium, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Equillium, Inc. (“Equillium” or the “Company”) (NASDAQ:EQ), in connection with its takeover of Metacrine, Inc. (Metacrine) (NASDAQ: MTCR). Under the terms of the merger agreement, Equillium will issue stock valued at a 25% premium over the Metacrine net cash delivered at closing, which is estimated to be approximately $26 million.

Join Case →

November 23, 2022

Metacrine, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Metacrine, Inc. (“Metacrine” or the “Company”) (NASDAQ:MTCR), in connection with the acquisition of the Company by Equillium, Inc. (“Equillium”)(NASDAQ: EQ). Under the terms of the merger agreement, Equillium will issue stock valued at a 25% premium over the net cash delivered at closing, which is estimated to be approximately $26 million.

Join Case →

We will fight for you and have your back no matter what. Join the tens of thousands of people we’ve helped.

Cases

Search for a case

Cases

PSB Holding Corp. Investigation

Weber Inc. Investigation

Coupa Software Incorporated Investigation

Horizon Therapeutics Public Limited Company Investigation

Vivint Smart Home, Inc. Investigation

Salisbury Bancorp, Inc. Investigation

Apollo Endosurgery, Inc. Investigation

Equillium, Inc. Investigation

Metacrine, Inc. Investigation

Where to find us?

new york

california

georgia

NEW JERSEY